- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01954030
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure
The primary objectives of the study are to determine the maximum tolerated dose (MTD) of Carboxyamidotriazole Orotate (CTO) when combined with standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO grade III or IV) that have previously failed bevacizumab (Phase 1); to determine the activity of CTO alone in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 1); to determine the activity of CTO plus bevacizumab in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 2).
This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and bevacizumab had been determined for this population. Phase 2 will not proceed.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
In Phase 1 of the study, we will conduct a dose-escalation study of the combination of CTO with the standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO Grade III or IV) that have previously failed bevacizumab. All patients will have also received standard treatment with radiation therapy and temozolomide prior to enrollment on study.
The Phase 2 portion of this study will investigate two novel treatment regimens sequentially. Each regimen will include 25 patients with recurrent WHO grade IV malignant glioma who have been treated in the past with standard radiation therapy, temozolomide, and bevacizumab. All patients must have failed therapy while on bevacizumab. Subjects in the first treatment regimen will receive CTO alone and subjects in the second treatment regimen will receive the combination of CTO and bevacizumab together.
Note: This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and bevacizumab had been determined for this population. Phase 2 will not proceed.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- The Preston Robert Tisch Brain Tumor Center at Duke
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Phase 1 portion: Patients must have recurrent histologically confirmed diagnosis of World Health Organization (WHO) grade III or IV malignant glioma with no more than 3 prior progressions
- Phase 2 portion: Patients must have recurrent histologically confirmed diagnosis of WHO grade IV malignant glioma (glioblastoma or gliosarcoma) with no more than 3 prior progressions.
- Must have had a least 1 prior progression on a bevacizumab-containing regimen
- Age greater than or equal to 18 years
- Karnofsky ≥ 70%
- Bi-dimensionally measurable disease, as assessed by magnetic resonance imaging based on The Revised Assessment in Neuro-Oncology (RANO) criteria
- Absolute neutrophil count (ANC) ≥1000 cells/µl, Platelets ≥ 100,000 cells/µl (without transfusion within 14 days before enrollment)
- Adequate renal function as indicated by the following: Serum creatinine < 1.25 times upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 ml/min; Urine dipstick for proteinuria < 2+ unless a 24-hour urine protein <1 g of protein is demonstrated
- Prothrombin time (PT) ≤ 1.5 x ULN and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN within 14 days prior to first study treatment for patients not receiving anti-coagulation. The use of full-dose oral or parenteral anticoagulants is permitted as long as the PT or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment.
- For patients on corticosteroids, they must be on a stable dose for 7 days prior to anticipated start of study drug, and the dose should not be escalated over entry dose level, if clinically possible
- Signed informed consent approved by the Institutional Review Board
- No evidence of > grade 1 active central nervous system (CNS) hemorrhage on the baseline magnetic resonance imaging (MRI) or computed tomography (CT) scan
- Female patients must not be pregnant or breast-feeding. Female patients of childbearing potential (defined as < 2 years after last menstruation or not surgically sterile) must use a highly effective contraceptive method (allowed methods of birth control, [i.e. with a failure rate of < 1% per year] are implants, injectables, combined oral contraceptives, intra-uterine device (IUD) (only hormonal), sexual abstinence or vasectomized partner) during the trial and for a period of > 6 months following the last administration of trial drug(s). Female patients with an intact uterus (unless amenorrhea for the last 24 months) must have a negative serum pregnancy test within 48 hours prior to first study treatment.
- Fertile male patients must agree to use a highly effective contraceptive method (allowed methods of birth control [i.e. with a failure rate of < 1% per year] include a female partner using implants, injectables, combined oral contraceptives, IUDs [only hormonal], sexual abstinence or prior vasectomy) during the trial and for a period of > 6 months following the last administration of trial drugs.
Exclusion Criteria:
- Pregnancy or breast-feeding
- Co-medication that may interfere with study results, for example, immuno-suppressive agents other than corticosteroids
- Active infection requiring intravenous (IV) antibiotics within 7 days before enrollment
- Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin
- Taking cytochrome P450 3A4 (CYP3A4) inducers and moderate or strong inhibitors (Note: Corticosteroids are allowed, as long as patients have been on a stable dose for 7 days prior to anticipated start of study drug, and the dose should not be escalated over entry dose level, if clinically possible)
- Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or progression on 2 consecutive scans or histopathologic confirmation
- Treated with immunotherapeutic agents or vaccines within 4 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Treated with alkylating agents within 4 weeks before enrollment or treated with daily or metronomic chemotherapy within 1 week before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Prior chemotherapy (non-alkylating agents) within 2 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Current, recent (within 4 weeks of the first infusion of this study) use of an experimental drug, unless the patient has recovered from the expected toxic effects of study therapy
Vascular endothelial growth factor (VEGF) Inhibitor-Specific Exclusion Criteria are:
- Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) within 28 days of first study treatment
- Prior history of hypertensive crisis, hypertensive encephalopathy, reverse posterior leukoencephalopathy syndrome (RPLS)
- Prior history of gastrointestinal perforation or abscess
- Clinically significant (active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade 2 or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment
- History or evidence upon physical/neurological examination of central nervous system disease (for example, seizures) unrelated to cancer unless adequately controlled by medication or potentially interfering with protocol treatment
- Significant vascular disease (for example, aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment
- History of pulmonary hemorrhage/hemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month of first study treatment
- History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (in the absence of therapeutic anticoagulation)
- Current or recent (within 10 days of study enrollment) use of aspirin (> 325 mg/day), clopidogrel (> 75 mg/day) or equivalent. Prophylactic or therapeutic low molecular weight heparin (LMWH) is allowed.
- Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study
- Minor surgical procedure, for example, stereotactic biopsy, within 7 days of first study treatment; placement of a vascular access device, within 2 days of first study treatment
- History of intracranial abscess within 6 months prior to first study treatment
- History of active gastrointestinal bleeding within 6 months prior to first study treatment
- Serious, non-healing wound, active ulcer, or untreated bone fracture
- Known hypersensitivity to any component of bevacizumab or CTO
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: CTO and Bevacizumab (Phase 1)
The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
|
Andere namen:
|
Experimenteel: Phase 2: CTO alone (Phase 2)
The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
|
Andere namen:
|
Experimenteel: CTO and Bevacizumab (Phase 2)
The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
|
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Phase 1: Determine the Maximum Tolerated Dose (MTD) of CTO when combined with standard dosing of bevacizumab
Tijdsspanne: 1 year
|
A standard "3+3" design to determine the MTD of CTO in combination with bevacizumab.
Subjects will be administered CTO orally on a continuous daily dosing schedule, while subjects will receive bevacizumab (10 mg/kg) every 2 weeks.
Cohorts of 3-6 subjects will accrue at each dose level of CTO, beginning with 225 mg/m2, until MTD is defined.
The MTD is the highest dose level at which ≤ 1 out of 6 experienced a dose limiting toxicity (DLT).
|
1 year
|
Phase 2: Percentage of subjects who remain alive and progression-free at 6 months
Tijdsspanne: 2 years
|
Percentage of participants surviving six months from start of study treatment without progression of disease.
Progression-free survival (PFS) was defined as the time from start of study treatment to the date of the first documented progression according to the Response Assessment in Neuro-Oncology (RANO) criteria, or to death due to any cause.
|
2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Fase 2: Percentage proefpersonen dat een dosisbeperkende toxiciteit (DLT) ervaart tijdens een cyclus van protocolbehandeling
Tijdsspanne: 2 jaar
|
Alle toxiciteiten worden verzameld met behulp van Common Terminology Criteria for Adverse Events (CTCAE) versie 4.0. DLT's worden gedefinieerd als een van de volgende gebeurtenissen die mogelijk, waarschijnlijk of zeker toe te schrijven zijn aan CTO of lomustine: Niet-hematologisch:
Hematologische:
|
2 jaar
|
Phase 1: Number of subjects who experience a dose-limiting toxicity (DLT) during cycle 1
Tijdsspanne: 1 year
|
All toxicities will be collected using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DLTs will be defined as any of the following events that are possibly, probably, or definitely attributable to CTO or lomustine: Non-hematologic:
Hematologic:
|
1 year
|
Phase 2: Median Overall Survival (OS)
Tijdsspanne: 2 years
|
Time in months from start of study treatment to date of death due to any cause.
Patients alive as of the last follow-up will have OS censored at the last follow-up date.
Median OS will be estimated using a Kaplan-Meier curve.
|
2 years
|
Phase 2: 6 and 12 month Overall Survival (OS)
Tijdsspanne: 2 years
|
Percentage of participants surviving 6 and 12 months from start of study treatment.
OS is defined as time from start of study treatment to the date of death due to any cause.
|
2 years
|
Phase 2: Percentage of subjects with best overall response (BOR) of complete response (CR) or partial response (PR)
Tijdsspanne: 2 years
|
Response is based on Response Assessment in Neuro-Oncology (RANO) criteria as determined by investigator assessment.
A confirmation of response was not required.
Complete Response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.
Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.
|
2 years
|
Phase 2: Median PFS
Tijdsspanne: 2 years
|
Time in months from start of study treatment to the date of first progression according to RANO criteria, or to death due to any cause.
Patients alive who had not progressed as of the last follow-up will have PFS censored at the last follow-up date.
Median PFS will be estimated using a Kaplan-Meier curve.
|
2 years
|
Phase 2: 12 month PFS
Tijdsspanne: 2 years
|
Percentage of participants surviving six months from the start of study treatment without progression of disease.
PFS is defined as the time from the date of study treatment initiation to the date of the first documented progression according to the RANO criteria, or to death due to any cause.
|
2 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Neoplasmata, glandulair en epitheel
- Neoplasmata, neuro-epitheliaal
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Glioom
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Antineoplastische middelen
- Antineoplastische middelen, immunologisch
- Angiogenese-remmers
- Angiogenese modulerende middelen
- Groei stoffen
- Groeiremmers
- Membraantransportmodulatoren
- Calciumregulerende hormonen en middelen
- Calciumantagonisten
- Bevacizumab
- Carboxyamido-triazool
Andere studie-ID-nummers
- Pro00044274
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Kwaadaardig glioom (WHO graad III of IV)
-
Beijing Tiantan HospitalZhongSheng BioTech Inc.WervingWHO graad III gliomen | WHO graad IV gliomenChina
-
Children's Hospital Medical Center, CincinnatiBeëindigdGlioblastoom Multiforme (WHO Graad IV) | Anaplastisch astrocytoom (WHO Graad III)Verenigde Staten
-
University of GöttingenHannover Medical School; Deutsche KinderkrebsstiftungWervingInternationale coöperatieve fase III-studie van de HIT-HGG-studiegroep (HIT-HGG-2013) (HIT-HGG-2013)Diffuus intrinsiek ponsglioom | Gliomatose Cerebri | Glioblastoom WHO Graad IV | Diffuse middenlijn glioom Histon 3 K27M WHO graad IV | Anaplastisch astrocytoom WHO Graad IIIDuitsland
-
Artiva Biotherapeutics, Inc.WervingLupus Nefritis - WHO-klasse IV | Lupus-nefritis - WHO-klasse IIIVerenigde Staten
-
Kyverna TherapeuticsWervingLupus-nefritis | Lupus Nefritis - WHO-klasse IV | Lupus-nefritis - WHO-klasse IIIDuitsland
-
Kyverna TherapeuticsWervingLupus-nefritis | Lupus Nefritis - Wereldgezondheidsorganisatie (WHO) Klasse III | Lupus Nefritis - WHO-klasse IVVerenigde Staten
-
Michael Vogelbaum, MD, PhDInfuseon Therapeutics, Inc.VoltooidKwaadaardig glioom | WHO graad III of IV recidiverend glioomVerenigde Staten
-
Annick DesjardinsTactical Therapeutics, Inc.BeëindigdKwaadaardig glioom (WHO graad III of IV)Verenigde Staten
-
Rigel PharmaceuticalsNationwide Children's HospitalNog niet aan het wervenAstrocytoom | Hooggradig glioom | Oligodendroglioom | Diffuus intrinsiek ponsglioom | Diffuus middellijnglioom, H3 K27M-mutant | WHO graad III glioom | Metastatische hersentumor | Spinale tumor | Astrocytoom, graad III | Astrocytoom, graad IV | IDH1-mutatie | WHO Graad IV Glioom | Thalamus-tumor | IDH1 R132 | IDH1 R132C en andere voorwaardenVerenigde Staten, Australië, Verenigd Koninkrijk, Canada, Duitsland, Nederland
-
Nationwide Children's HospitalNovartisNog niet aan het wervenGlioblastoom | Glioblastoom Multiforme | Hooggradig glioom | Anaplastisch astrocytoom | Diffuus intrinsiek ponsglioom | Diffuus middellijnglioom, H3 K27M-mutant | WHO graad III glioom | Metastatische hersentumor | WHO Graad IV GlioomVerenigde Staten, Australië, Verenigd Koninkrijk, Canada, Duitsland, Nederland
Klinische onderzoeken op CTO and Bevacizumab
-
Corindus Inc.BeëindigdCoronaire hartziekte | Percutane coronaire interventie | Chronische totale occlusie van kransslagaderVerenigde Staten
-
The First Affiliated Hospital with Nanjing Medical...WervingChronische totale occlusie van kransslagaderChina
-
Leif ThuesenWervingHartfalen | Angina pectoris | Chronische totale occlusie van kransslagaderDenemarken
-
SoundBite Medical Solutions, Inc.Voltooid
-
Universitätsmedizin MannheimIHF GmbH - Institut für Herzinfarktforschung; Herzzentrum LahrNog niet aan het wervenCoronaire hartziekte | Hartfalen | Chronische totale occlusie
-
Kerckhoff Heart CenterInstitute of Cardiology, Warsaw, Poland; University of Giessen; University Hospital...VoltooidCoronaire hartziekteDuitsland, Polen
-
Yale UniversityBoston Scientific CorporationBeëindigdSymptomatische femoro-popliteale chronische totale occlusieVerenigde Staten
-
Ureca BVBeëindigd
-
AngioSafe, Inc.Veranex, Inc.WervingPerifere arteriële ziekte | Perifere slagaderocclusieVerenigde Staten
-
Tactical Therapeutics, Inc.Actief, niet wervendVaste tumoren, glioblastoom, terugkerende kwaadaardige gliomenVerenigde Staten